[CAS NO. 1617-90-9] Vincamine
PRODUCTS SPECIFICATIONS [1617-90-9]
DESCRIPTION [1617-90-9]
Overview
| MDL | MFCD00078054 |
|---|---|
| Molecular Weight | 354.44 |
| Molecular Formula | C21H26N2O3 |
| SMILES | O=C(OC)[C@@]1(O)C[C@@]2(CC)[C@@]3([H])C(N1C4=CC=CC=C54)=C5CCN3CCC2 |
Summary
Vincamine is a monoterpenoid indole alkaloid extracted from the Madagascar periwinkle . Vincamine is a peripheral vasodilator and exerts a selective vasoregulator action on the brain microcapilar circulation [1] . Vincamine is a GPR40 agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS). Vincamine improves glucose homeostasis in vivo , and has the potential for the type 2 diabetes mellitus (T2DM) research [2] .
In Vitro
Vincamine (20, 40 and 80 μM; 24 hours) exerts a significant, concentration-dependent protective effect in LPS-treated human corneal epithelial cells (HCECs) cells
[1]
.
Vincamine (20, 40 and 80 μM; 24 hours) significantly reduces ROS level in a dose-dependent manner in LPS-treated human corneal epithelial cells (HCECs)cells. Additionally, after Vincamine administration, the levels of MDA is also significantly reduced while the levels of T-AOC, and SOD are increased in a dose-dependent manner
[1]
.
Vincamine (20, 40 and 80 μM; 24 hours) rescues TrxR activity in a dose-dependent manner in HCECs. However, the intracellular activities of Trx, GR and GPx are neither inhibited nor activated by both LPS and Vincaminer
[1]
.
Vincamine could activate GPR40 (EC
50
=6.28 µM) with DHA (GPR40 ligand) as a positive control (EC
50
=3.85 µM) in hGPR40-CHO cells
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Vincamine (intraperitoneal injection; 15 and 30 mg/kg/day; 6 weeks) improves glucose tolerance in type 2 diabetic model mice. It effectively lowers the levels of fasting blood glucose and glycated hemoglobin. At the same time, it ameliorates oral glucose tolerance and elevated glucose-induced plasma insulin concentration without influence on basal insulin secretion in vivo [2] .<.br>
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Male and female db/db mice (BKS.Cg- Dock 7m+/+ Lepr db /J) and HFD/STZ-induced type 2 diabetic model mice |
| Dosage: | 15 and 30 mg/kg/day |
| Administration: | Intraperitoneal injection; 15 and 30 mg/kg/day; 6 weeks |
| Result: | Enhanced glucose tolerance in HFD/STZ and db/db male mice. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 25 mg/mL ( 70.53 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.8214 mL | 14.1068 mL | 28.2135 mL |
| 5 mM | 0.5643 mL | 2.8214 mL | 5.6427 mL |
| 10 mM | 0.2821 mL | 1.4107 mL | 2.8214 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (7.05 mM); Clear solution
References
- [1] Te Du, et al. Vincamine as a GPR40 agonist improves glucose homeostasis in type 2 diabetic mice. J Endocrinol. 2019 Feb 1;240(2):195-214.
- [2] Li Wu, et al. Vincamine prevents lipopolysaccharide induced inflammation and oxidative stress via thioredoxin reductase activation in human corneal epithelial cells. Am J Transl Res. 2018 Jul 15;10(7):2195-2204. eCollection
Synonyms